Boston Scientific to Acquire Penumbra in $15B Deal

Boston Scientific announced a $15B cash-and-stock agreement to acquire Penumbra, a maker of neurovascular and thrombectomy devices. Strategic and financial implications for the interventional radiology/neuroIR device market remain under analyst debate.

• Boston Scientific announced the acquisition agreement earlier in 2025; the deal is valued at approximately $15B in cash and stock.
• Penumbra is known for its neurovascular embolization and large-vessel thrombectomy platforms, making this a significant move into neuroIR and peripheral vascular device markets.
• This is opinion/analysis from a blog source — independent financial or regulatory confirmation of strategic outcomes is not yet available; treat claims accordingly.

RadPigeon summaries are original and for information only. They are not clinical advice.